Forecast of $0.24 EPS for Imperva, Inc. According to Zacks Investment Research

Forecast of $0.24 EPS for Imperva Inc.

Zacks reports that Wall Street brokerages forecast an $0.24 EPS for Imperva Inc. (NYSE:$IMPV). The estimates range from $0.26 to $0.23. During the same quarter last year, Imperva reported a $0.08, which would indicate a 200% growth rate. Earnings results are predicted to arrive Thursday, November 2nd.

Zacks also reported that analysts forecast full year earnings of $0.81 for the current year. Exact estimates ranged from $0.79 to $0.83. EPS estimates range from $0.73 to $1.04 for an average annualized EPS forecast of $0.94 per share.

On Tuesday, trading of Imperva opened at $43.20. Their market cap currently is currently at $1.46 billion. They have a 50 day moving average of $44.11 and a 200 day moving average of $45.69. Their current 52 week high is $57.24 and their 52 week low is $34.40.

The last earnings result report was issued by Imperva on Thursday, July 27th. They beat the consensus estimate of -$0.15 with a reported -$0.10 EPS. During the same quarter the previous year, the company reported -$0.23. They reported revenue of $74.44 million, just beating the consensus estimates of $74.30 million. On a year-over-year basis, total revenue was up 28.6%. They also reported a negative Net Margin of -4.69% and a negative Return on Equity of -5.00%.

Multiple analyst firms also recently weighed in on the stock;

  • Susquehanna Bancshares Inc: On Wednesday, June 7th, the firm commenced coverage of the stock with a ‘Positive’ rating and a price target of $60.00.
  • Stephens: On Thursday, July 13th, Stephens restated an ‘Overweight’ rating and increased their target price from $53.00 to $61.00.
  • Evercore ISI: In a report on Friday, July 28th, Evercore gave the company a ‘Buy’ rating and a price target of $56.00.
  • Monness Crespi & Hardt: Also on Friday, July 28th, this firm gave the company a ‘Buy’ rating and upped their price target from $55.00 to $57.00.
  • ValuEngine: Finally, on Tuesday, July 11th, ValuEngine dropped shares of Imperva from ‘Hold’ to ‘Sell’.

In insider news, Director Anthony J. Bettencourt sold 99,598 shares for an average price of $43.59 with a total value of $4,341,476.82. The transaction took place on Thursday, August 24th. He currently owns 99,598 shares valued at $4,341,476.82. All together, insiders currently own 2.20% company’s stock.

Multiple institutions recently altered their holdings in the company;

  • ETF Managers Group LLC bought a new stake in the company during the 2nd quarter with an initial investment of $41,888,000.
  • Clearbridge Investments LLC bought an additional 403,809 shares in the 1st quarter, an increase of 47.0%, giving them a total of 1,262,507 shares valued at $51,826,000.
  • Eagle Asset Management Inc bought an additional 192,625 shares during the 2nd quarter, for a total of 1,279,848 shares valued at $61,240,000.
  • BlackRock Inc bought an additional 215,170 shares during their 2nd quarter, an increase of 11.3%, for a total of 2,124,043 shares valued at $101,635,000.
  • Vanguard Groups Inc. bought an additional 99,799 shares in the 2nd quarter, an increase of 4.3%, for a total of 2,439,240 shares valued at $116,718,000.

Institutional ownership currently accounts for 92.72% of the total active shares.

Featured Image: Depositphotos/© SergeyNivens

About the author: Dylan is a content writer and editor located in Vancouver, British Columbia. He graduated from the University of Regina with BA degrees in both Journalism and History in 2016. His skills include writing, blogging, editing, and developing content for both print and internet media.